Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.38 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407685 | 1.00 | ALOX5 (0.44) | ALOX5SLC8A1PPARGPPARAFAAH | |
| SCHEMBL6410142 | 0.91 | PDE4A (0.43) | ALOX5SLC8A1PPARAFFAR4PDE4A | |
| SCHEMBL6780340 | 0.91 | PDE4A (0.43) | ALOX5SLC8A1PPARAFFAR4PDE4A | |
| SCHEMBL6406090 | 0.91 | GABRA1 (0.45) | ALOX5SLC8A1PDE4APDE4BPDE4C | |
| SCHEMBL6413376 | 0.91 | GABRA1 (0.45) | ALOX5SLC8A1PDE4APDE4BPDE4C | |
| SCHEMBL6406371 | 0.91 | FFAR4 (0.41) | ALOX5SLC8A1FFAR4PDE4APDE4B | |
| SCHEMBL6405407 | 0.91 | FFAR4 (0.41) | ALOX5SLC8A1FFAR4PDE4APDE4B | |
| SCHEMBL6409847 | 0.91 | PPARG (0.39) | ALOX5PPARGPPARAFAAHFFAR4 | |
| SCHEMBL6405296 | 0.91 | PPARG (0.39) | ALOX5PPARGPPARAFAAHFFAR4 | |
| SCHEMBL6406536 | 0.85 | PTGS1 (0.47) | PPARAFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | G.D. SEARLE & CO. (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | PTGS2, PTGES2, PTGER2 | ALOX5 444/4885SLC8A1 3442/4885PPARG 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.